Read highlights from the latest installment of Dusko Ilic’s industry updates, which discuss the latest developments and news in regenerative medicine and stem cell research, and are published every month in Regenerative Medicine.
Every month, Dusko comments on news of note. Read the full update for July 2019 on Regenerative Medicine here>>
What happened this month that you were expecting?
Adaptimmune Therapeutics (Abingdon, UK) is flexing its muscle and expanding their clinical trials portfolio with a new generation of specific peptide enhanced affinity receptor T (SPEAR-T) cells.
What happened that surprised you this month?
Following their recent acquisition of Asterias Therapeutics and relocation of cellular therapy manufacturing to Israel, BioTime (CA, USA), a clinical-stage company from San Francisco Bay Area, made a surprising announcement: it is moving corporate headquarters to South California and taking a new name: Lineage Cell Therapeutics. This is the newest in a series of changes since Brian Culley has been appointed as the Company’s Chief Executive Officer and as a member of its Board of Directors in September 2018, succeeding Co-CEOs Adi Mohanty and Michael West.
If we only read about one story this month, what should it be?
The powerful launch of Century Therapeutics (PA, USA), with US$250 million financial commitments and back up from Bayer (Germany) and FUJIFILM Cellular Dynamics (WI, USA). The company is focused on development of allogeneic induced pluripotent stem cell therapies.
Dusko Ilic is a Senior Lecturer in stem cell science, coordinator of the cross-divisional postgraduate program in stem cells and regenerative medicine, and Head of the Induced Pluripotent Stem Cell Core Facility at King’s College London (London, UK). He is also Head of the Assisted Conception Unit’s Human Embryonic Laboratories at Guy’s Hospital (London, UK). He is also a member of the editorial board of the journal Regenerative Medicine, where he writes the Industry Report, a regular feature compiling information from non-academic institutions in the field of stem cells and regenerative medicine.